Filing Details

Accession Number:
0001415889-21-004350
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-10 18:13:35
Reporting Period:
2021-09-08
Accepted Time:
2021-09-10 18:13:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1800 Abbott Laboratories ABT Pharmaceutical Preparations (2834) 360698440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1712233 J Michael Pederson 100 Abbott Park Road
Abbott Park IL 60064
Senior Vice President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Without Par Value Acquisiton 2021-09-08 23,008 $50.72 85,579 No 4 M Direct
Common Shares Without Par Value Disposition 2021-09-08 23,008 $129.05 62,571 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Option (right to buy) Disposition 2021-09-08 23,008 $0.00 23,008 $50.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-07-21 2027-07-20 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares Without Par Value 75 Indirect By Spouse
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.03 to $129.09, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.